#1 Clinical Trials Search in Europe

Ly3454738

Clinical trials are studying Ly3454738 in adults with moderate-to-severe atopic dermatitis, also called eczema. These trials are looking at whether Ly3454738 is effective and how it compares with placebo in people who have not used biologic or small-molecule treatments before.

Table of Contents

Trial overview

The available trial studied Ly3454738 in adults with moderate-to-severe atopic dermatitis, which is a long-term skin condition also called eczema.[1]

This was an interventional study, which means the researchers gave a study treatment and measured the results.[1]

The trial was in Phase 2, a stage that looks for early signs that a treatment may work and continues to monitor safety.[1]

Who could join the study

The study was for adult participants with moderate-to-severe atopic dermatitis.[1]

It focused on people who were biologic-and-small-molecule naïve, meaning they had not used those treatment types before.[1]

This helps researchers understand how Ly3454738 performs in a group that has not been treated with these newer medicine types before.[1]

What was studied

The trial compared Ly3454738 with placebo, which is a look-alike treatment that does not contain the active study drug.[1]

The brief study summary says the main goal was to compare the efficacy, or how well the treatment works, of Ly3454738 versus placebo in this patient group.[1]

The trial included treatment given by subcutaneous injection, which means a shot under the skin.[1]

Trial endpoints and results being measured

The main endpoint was the percentage of participants who achieved EASI-75.[1]

EASI stands for Eczema Area and Severity Index, a score used to measure how severe eczema is.[1]

EASI-75 means the score improved by at least 75%, which shows a large improvement in eczema signs and symptoms.[1]

Trial design and treatment groups

The trial was designed as a comparison between Ly3454738 and placebo.[1]

The source data also lists topical treatments and sodium chloride solution in the intervention record, but the clearest study objective provided is the comparison of Ly3454738 versus placebo in moderate-to-severe atopic dermatitis.[1]

Because the source only gives a brief summary, the main patient-relevant detail is that the study tested whether Ly3454738 could improve eczema outcomes better than placebo in adults who had not used biologic or small-molecule therapies before.[1]

Study status and size

The trial is marked as completed.[1]

A total of 262 participants were enrolled.[1]

This makes it a moderate-sized Phase 2 study focused on eczema treatment research.[1]

Trial ID Phase Condition studied Status Enrollment
2022-502888-38-00 Phase 2 Atopic dermatitis Completed 262

FAQ

  • What is being studied in Ly3454738 trials? The trial is studying Ly3454738 in adults with moderate-to-severe atopic dermatitis. It is looking at whether the treatment helps improve eczema symptoms compared with placebo.
  • Who can take part in the study? The study is for adult participants with moderate-to-severe atopic dermatitis. It focuses on people who are biologic-and-small-molecule naïve, meaning they have not used those treatment types before.
  • What phase is the Ly3454738 trial? The trial is a Phase 2 study. Phase 2 trials usually check early signs of how well a treatment works and continue to watch safety.
  • What result is the trial measuring? The main result is EASI-75, which means at least a 75% improvement in the Eczema Area and Severity Index. This score is used to measure how severe eczema is and how much it improves.
  • What is the status of the trial? The study is completed. It enrolled 262 participants.

Ongoing Clinical Trials on Ly3454738

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Atopic dermatitis: A long-term skin condition, also called eczema, that can cause dry, itchy, and inflamed skin.
  • Moderate-to-severe: A level of illness that is more than mild and can cause a bigger impact on daily life.
  • Biologic-and-small-molecule naïve: A person who has not used biologic medicines or small-molecule treatments before.
  • Placebo: A treatment that looks like the study treatment but does not contain the active drug.
  • Phase 2: A clinical trial stage that looks for early signs that a treatment may work and continues safety checks.
  • Interventional study: A study where researchers give a treatment and measure what happens.
  • EASI: Eczema Area and Severity Index, a score used to measure how bad eczema is.
  • EASI-75: A result meaning the eczema score improved by at least 75%.
  • Enrollment: The number of people who joined the study.
  • Subcutaneous injection: A shot given under the skin.

References

  1. https://clinicaltrials.gov/study/2022-502888-38-00